Health Care [ 5/12 ] | Biotechnology [ 25/74 ]
NASDAQ | Common Stock
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases.
The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases.
It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation.
The company was incorporated in 2005 and is headquartered in Austin, Texas.
Reported date | EPSChange YoY | EstimateSurprise |
---|---|---|
Mar 13, 25 | -0.34 Decreased by -126.33% | - |
Nov 7, 24 | -0.16 Increased by +31.96% | - |
Aug 12, 24 | -0.43 Decreased by -48.68% | - |
May 10, 24 | -0.33 Decreased by -152.69% | - |
Mar 15, 24 | -0.15 Decreased by -44.77% | - |
Nov 9, 23 | -0.24 Increased by +42.40% | - |
Aug 11, 23 | -0.29 Increased by +24.42% | - |
May 10, 23 | -0.13 Increased by +27.78% | - |
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Dec 31, 24 | 0.00 Decreased by -100.00% | -10.51 M Decreased by -126.71% | Decreased by N/A% Decreased by N/A% |
Sep 30, 24 | 0.00 Decreased by N/A% | -5.01 M Increased by +31.90% | Decreased by N/A% Decreased by N/A% |
Jun 30, 24 | 0.00 Decreased by N/A% | -13.01 M Decreased by -48.78% | Decreased by N/A% Decreased by N/A% |
Mar 31, 24 | 2.62 M Increased by +N/A% | -10.00 M Decreased by -162.11% | Decreased by -381.76% Decreased by N/A% |
Dec 31, 23 | 2.62 M Increased by +773.33% | -4.63 M Decreased by -44.71% | Decreased by -176.91% Increased by +83.43% |
Sep 30, 23 | 0.00 Decreased by -100.00% | -7.36 M Increased by +41.82% | Decreased by N/A% Decreased by N/A% |
Jun 30, 23 | 0.00 Decreased by -100.00% | -8.74 M Increased by +24.92% | Decreased by N/A% Decreased by N/A% |
Mar 31, 23 | 0.00 Decreased by -100.00% | -3.82 M Increased by +29.27% | Decreased by N/A% Decreased by N/A% |